Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
09:30am, Tuesday, 05'th Mar 2024
Vertex Pharmaceuticals is angling to treat acute pain with its new drug. Compass Pathways will have a major data update sometime in Q4.
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
08:03am, Tuesday, 05'th Mar 2024
CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, d
Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up
01:11pm, Thursday, 29'th Feb 2024
Catalyst (CPRX) reports encouraging fourth-quarter results, driven by Firdapse and Fycompa sales. The stock gains in the pre-market session.
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
08:21pm, Wednesday, 28'th Feb 2024
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.22 per share a year ago.
CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
08:03am, Wednesday, 14'th Feb 2024
The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances
04:54am, Thursday, 18'th Jan 2024
The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession,
3 Biotech Stocks You Can Buy and Hold for the Next Decade
08:45am, Monday, 15'th Jan 2024
Catalyst buys appealing medicines or pharmaceutical assets and gets them out the door. Recursion uses AI and vast biomedical data to discover and exploit leads for new drugs.
5 Value Stocks With Strong Earnings Yield to Rev Up Returns
09:01am, Wednesday, 10'th Jan 2024
Consider investing in high-yield value stocks like GCT, SKYW, METC, EMN and CPRX to unlock your portfolio's potential.
New Strong Buy Stocks for January 10th
07:31am, Wednesday, 10'th Jan 2024
PCRFY, IMCR, CPRX, AMPX and ENS have been added to the Zacks Rank #1 (Strong Buy) List on January 10, 2024.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
10:32am, Wednesday, 03'rd Jan 2024
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Is Catalyst Pharmaceuticals (CPRX) Stock a Solid Choice Right Now?
09:46am, Tuesday, 02'nd Jan 2024
Catalyst Pharmaceuticals (CPRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
12:03pm, Sunday, 17'th Dec 2023
With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the digital
Catalyst (CPRX) Q3 Earnings Miss, Sales Top, '23 View Up
09:49am, Thursday, 09'th Nov 2023
Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales continue to boost revenues.
Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
08:03am, Monday, 23'rd Oct 2023
The Company to Host a Conference Call and Webcast on November 9, 2023, at 8:30 AM ET The Company to Host a Conference Call and Webcast on November 9, 2023, at 8:30 AM ET
